CFO — Michael Grasher: The filing announces the external hire of a new CFO to replace an interim officer, which is a significant management change but not a departure of a sitting executive.

Director — David B. Snow, Jr.: The filing concerns the retirement of a board director for personal reasons, which is a routine governance event and not a departure of senior executive management.

Director — Mark V. Anquillare: Mr. Anquillare was appointed as a director and joined the audit committee and compensation committee.

Results of Operations and Financial Condition. On July 29, 2026, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the second quarter of 2026. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in

Results of Operations and Financial Condition. On April 29, 2026, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the first quarter of 2026. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in

Director — Susan R. Salka: Appointment of Susan R. Salka as a director and to the audit committee and compensation committee.

Results of Operations and Financial Condition. On February 25, 2026, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the fourth quarter and full year 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in

Director — Michael S. Smith: The Board appointed Michael S. Smith as a director and increased the number of directors to ten.

Director — Mr. Thomas G. McKinley: Mr. Thomas G. McKinley retired from the Board for personal reasons.

Director — Mr. J. Eric Evans: Mr. J. Eric Evans is retiring from the Board for personal reasons.

The filing is about an amendment to the stock reserve under a compensatory plan, not a management change.

Results of Operations and Financial Condition. On October 29, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the third quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in

Results of Operations and Financial Condition. On October 23, 2025, Teladoc Health, Inc. (the “Company” or “we”) issued a press release announcing preliminary results for the quarter ended September 30, 2025. These financial results are preliminary, unaudited and subject to change in connection with the completion of the Company’s financial closing process and the preparation of its financial statements for the third quarter of 2025. In addition, the Company announced that it continues to exp…

The report contains forward-looking statements and cautionary notes, not management changes.

Results of Operations and Financial Condition. On July 29, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the second quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in

Entry into a Material Definitive Agreement . On July 17, 2025 (the “Effective Date”), Teladoc Health, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”), issuing bank and swingline lender, and the lenders party thereto. The Credit Agreement provides for a five-year, $300 million senior secured revolving credit facility (the “Revolving Credit Facility”). The Company…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

The filing is about an amendment to the Incentive Award Plan and does not involve any management changes.

Results of Operations and Financial Condition. On April 30, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the first quarter of 2025. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in

Results of Operations and Financial Condition. On February 26, 2025, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the fourth quarter and full year 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in

Results of Operations and Financial Condition. On October 30, 2024, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the third quarter of 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in

Chief Operating Officer — Michael Waters: Mr. Waters resigned due to a change in the Company's executive reporting structure.

Senior Vice President and Chief Accounting Officer — Joseph Catapano: The company hired a new Senior Vice President and Chief Accounting Officer.

Results of Operations and Financial Condition. On July 31, 2024, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the second quarter of 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in

President, Enterprise Growth and Global Markets — Laizer Kornwasser: Mr. Kornwasser's employment was terminated without cause in connection with a change in the Company's executive reporting structure.